Rockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement

Rockwell Medical, Inc.

, a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a permanent unique product reimbursement code for Triferic. The Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement J-code (J1443) will become effective on January 1, 2016. Triferic is the only FDA approved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients in the United States.